Alaunos Therapeutics Inc (TCRT)

May 14, 2025, 8:00 AM EDT - 23 days ago

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

ELAB

Nov 14, 2023, 7:30 AM EST - 1 year ago

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

Aug 21, 2023, 7:32 AM EDT - 1 year ago

Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)

ALLK BLFS KZR

Aug 14, 2023, 4:05 PM EDT - 1 year ago

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

Jun 29, 2023, 7:00 AM EDT - 2 years ago

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

May 25, 2023, 5:00 PM EDT - 2 years ago

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

May 10, 2023, 3:40 PM EDT - 2 years ago

Alaunos Therapeutics, Inc. (TCRT) Q1 2023 Earnings Call Transcript

May 10, 2023, 7:00 AM EDT - 2 years ago

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

May 3, 2023, 8:30 AM EDT - 2 years ago

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

Apr 26, 2023, 12:30 PM EDT - 2 years ago

Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Mar 30, 2023, 7:00 AM EDT - 2 years ago

Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

Mar 29, 2023, 5:30 PM EDT - 2 years ago

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April

Mar 7, 2023, 10:35 AM EST - 2 years ago

Alaunos Therapeutics, Inc. (TCRT) Q4 2022 Earnings Call Transcript

Mar 7, 2023, 7:00 AM EST - 2 years ago

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 28, 2023, 4:01 PM EST - 2 years ago

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

Jan 9, 2023, 8:30 AM EST - 2 years ago

Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023

Nov 29, 2022, 9:01 AM EST - 2 years ago

Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 28, 2022, 4:01 PM EST - 2 years ago

Alaunos Therapeutics Announces Proposed Public Offering of Common Stock

Nov 21, 2022, 2:13 PM EST - 2 years ago

Alaunos Therapeutics Still Waiting For Home Run

Nov 14, 2022, 2:10 PM EST - 2 years ago

Alaunos Therapeutics, Inc. (TCRT) Q3 2022 Earnings Call Transcript

Nov 14, 2022, 7:00 AM EST - 2 years ago

Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

Nov 8, 2022, 8:30 AM EST - 2 years ago

Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022

Nov 7, 2022, 8:00 AM EST - 2 years ago

Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting

Sep 21, 2022, 8:30 AM EDT - 2 years ago

Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Sep 14, 2022, 9:28 PM EDT - 2 years ago

Alaunos Therapeutics - T-Cell Therapies

Sep 7, 2022, 8:30 AM EDT - 2 years ago

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 31, 2022, 4:00 PM EDT - 3 years ago

Alaunos: Taking Autologous T-Cell Receptor Therapies To The Next Step

Aug 24, 2022, 3:00 PM EDT - 3 years ago

Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Aug 15, 2022, 12:01 PM EDT - 3 years ago

Alaunos Therapeutics, Inc. (TCRT) CEO Kevin Boyle on Q2 2022 Results - Earnings Call Transcript

Aug 15, 2022, 7:00 AM EDT - 3 years ago

Alaunos Therapeutics Reports Second Quarter 2022 Financial Results

Aug 8, 2022, 8:50 AM EDT - 3 years ago

Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022

Aug 4, 2022, 5:00 PM EDT - 3 years ago

Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations

Jun 1, 2022, 11:39 AM EDT - 3 years ago

CellChorus Announces Scientific Advisory Board

Jun 1, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Present at the Jefferies Healthcare Conference

May 26, 2022, 5:01 PM EDT - 3 years ago

Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting

May 16, 2022, 12:31 PM EDT - 3 years ago

Alaunos Therapeutics, Inc. (TCRT) CEO Kevin Boyle on Q1 2022 Results - Earnings Call Transcript

May 16, 2022, 7:30 AM EDT - 3 years ago

Alaunos Therapeutics Reports First Quarter 2022 Financial Results

May 10, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 9, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022

May 2, 2022, 4:31 PM EDT - 3 years ago

Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting

May 2, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors

Mar 30, 2022, 11:38 AM EDT - 3 years ago

Alaunos Therapeutics, Inc. (TCRT) Kevin Boyle on Q4 2021 Results - Earnings Call Transcript

Mar 30, 2022, 7:30 AM EDT - 3 years ago

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Mar 16, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022

Mar 8, 2022, 4:05 PM EST - 3 years ago

Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Jan 26, 2022, 11:19 AM EST - 3 years ago

Ziopharm Rebrands As Alaunos Therapeutics

Jan 26, 2022, 7:00 AM EST - 3 years ago

Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

Nov 9, 2021, 8:05 AM EST - 3 years ago

Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting

Nov 8, 2021, 7:45 PM EST - 3 years ago

ZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call Transcript

Nov 8, 2021, 4:10 PM EST - 3 years ago

Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update